An example of the success of this approach is illustrated by Amivantamab (Rybrevant), which targets epidermal growth factor (EGFR) and tyrosine kinase receptors (c-MET) (EGFR x c-MET) and was approved in May 2021 for non-small cell lung cancer treatment [10]. Here, EGFR is linked to non-small cell lung carcinoma.